This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

8 Big Acquirers of 2011

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

8. Teva Pharmaceutical Industries (TEVA - Get Report) makes and sells generic drugs.

In October, Teva completed the acquisition of Cephalon for a total consideration of $6.15 billion in cash, as per data compiled by Bloomberg. Pursuant to the acquisition, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.

Teva foresees realizing annual cost synergies of at least $500 million within three years of the transaction's closing.

Non-GAAP diluted earnings per share for full year 2011 are estimated in the range of $4.92 to $5.02, including non-GAAP diluted earnings per share contribution of approximately 15 cents from the consolidation of the Cephalon acquisition. The acquisition is seen supporting Teva's long-term strategy of achieving more than $9 billion revenue in 2015, as compared to $4.6 billion in 2010.

Of the 36 analysts covering the stock, 75% rate it a buy. On average, analysts polled by Bloomberg expect the stock to gain 29% to $53.77 in the coming 12 months.

>>To see these stocks in action, visit the 8 Big Acquirers of 2011 portfolio on Stockpickr.
8 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANR $0.04 3.17%
ECL $106.63 0.00%
DHR $84.92 0.00%
ESRX $67.34 0.00%
ESV $8.38 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs